tiprankstipranks
Trending News
More News >
Korro Bio (KRRO)
NASDAQ:KRRO
US Market
Advertisement

Korro Bio (KRRO) AI Stock Analysis

Compare
461 Followers

Top Page

KRRO

Korro Bio

(NASDAQ:KRRO)

Rating:45Neutral
Price Target:
Korro Bio's stock score reflects its current position as a developmental biotech firm. Financial performance is the most significant factor, showing the challenges of high R&D costs and reliance on external funding. The technical analysis suggests short-term downward pressure, while valuation is impacted by its negative earnings and lack of dividends. The company needs to focus on operational efficiency and revenue growth to improve its stock performance.
Positive Factors
Financial Position
KRRO ended with $139M in cash/equivalents, which offers runway into 2027.
Regulatory Advantage
KRRO-110 has been granted orphan drug designation by the European Medicines Agency, which is a positive development for its potential treatment of Alpha-1 Antitrypsin Deficiency.
Stock Performance
Competitor data, such as from WVE-006, has previously had a significant positive impact on KRRO's stock price, indicating potential for future stock performance improvements.
Negative Factors
Clinical Risks
Risks include delays in advancing pipeline candidates into and through clinical assessment, failure to generate favorable clinical data from ongoing programs, particularly KRRO-110 in AATD, and possible long-term dilution risk.
Workforce Reduction
Management announced a restructuring program, aiming to extend the runway into 2027, thereby allowing for clinical readouts/derisking of the two lead programs.

Korro Bio (KRRO) vs. SPDR S&P 500 ETF (SPY)

Korro Bio Business Overview & Revenue Model

Company DescriptionKorro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
How the Company Makes MoneyKorro Bio makes money primarily through the development and commercialization of its RNA editing therapies. The company generates revenue by partnering with pharmaceutical and biotechnology companies for licensing its technology, as well as through research collaborations. These partnerships often involve upfront payments, milestone payments based on development progress, and royalties on sales of any resulting therapies. Additionally, Korro Bio may receive funding from grants and research initiatives focused on advancing genetic medicine. The company's revenue streams are significantly influenced by its ability to advance its therapies through clinical development and regulatory approval, which in turn attract investment and partnering opportunities.

Korro Bio Financial Statement Overview

Summary
Korro Bio's financials reflect a typical biotech profile with high R&D costs and reliance on external financing. The income statement shows a recent move from zero revenue to some revenue, but with substantial losses. The balance sheet is mixed, with strong cash reserves but past equity concerns. Cash flow is negative, highlighting operational struggles.
Income Statement
45
Neutral
Korro Bio has seen significant challenges in generating revenue, with a recent turnaround from zero revenue to a small amount. However, the company continues to face substantial losses with a negative net profit margin. The gross profit margin is positive, but EBIT and EBITDA margins are deeply negative, indicating high operational costs that outweigh revenue.
Balance Sheet
55
Neutral
The balance sheet presents a mixed picture. On one hand, the company has a strong equity position and cash reserves, with a low debt-to-equity ratio suggesting limited leverage. However, the negative stockholders' equity in earlier years poses a concern about financial stability, though recent improvements are visible.
Cash Flow
50
Neutral
Cash flow analysis indicates that the company is struggling with negative operating and free cash flows, which is common for biotech firms focusing on R&D. There is, however, a significant inflow from financing activities, suggesting reliance on external funding to support operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.27M0.000.0014.07M36.98M
Gross Profit2.27M-3.63M-2.51M10.23M35.40M
EBITDA-88.34M-80.90M-56.49M-33.90M-24.90M
Net Income-83.58M-81.17M-58.03M-21.96M-26.51M
Balance Sheet
Total Assets226.24M221.66M73.74M127.58M264.72M
Cash, Cash Equivalents and Short-Term Investments126.09M166.15M55.25M118.53M220.34M
Total Debt44.77M33.21M3.13M45.60M45.99M
Total Liabilities65.83M51.75M172.77M169.78M72.23M
Stockholders Equity160.41M169.91M-99.03M-42.21M192.49M
Cash Flow
Free Cash Flow-77.98M-75.12M-58.86M-36.54M-51.86M
Operating Cash Flow-60.07M-67.28M-53.65M-32.09M-45.19M
Investing Cash Flow-123.35M11.16M11.06M-39.50M10.40M
Financing Cash Flow69.36M187.76M18.00K115.94M56.69M

Korro Bio Technical Analysis

Technical Analysis Sentiment
Positive
Last Price15.90
Price Trends
50DMA
13.49
Positive
100DMA
15.84
Positive
200DMA
30.48
Negative
Market Momentum
MACD
0.46
Negative
RSI
60.73
Neutral
STOCH
72.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRRO, the sentiment is Positive. The current price of 15.9 is above the 20-day moving average (MA) of 13.49, above the 50-day MA of 13.49, and below the 200-day MA of 30.48, indicating a neutral trend. The MACD of 0.46 indicates Negative momentum. The RSI at 60.73 is Neutral, neither overbought nor oversold. The STOCH value of 72.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KRRO.

Korro Bio Risk Analysis

Korro Bio disclosed 89 risk factors in its most recent earnings report. Korro Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Korro Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
52
Neutral
$564.95M-53.82%44.85%
52
Neutral
$296.61M-99.23%-40.10%-16.60%
51
Neutral
$317.37M123.38%10.49%47.31%
46
Neutral
$213.56M-32.97%
45
Neutral
$149.31M-60.22%85.19%
28
Underperform
$46.36M-41.96%72.12%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
KRRO
Korro Bio
15.90
-36.58
-69.70%
RGLS
Regulus
8.16
6.38
358.43%
ADCT
ADC Therapeutics
3.23
-0.40
-11.02%
KLRS
Kalaris Therapeutics
2.84
-15.24
-84.29%
SLN
Silence Therapeutics
6.28
-14.71
-70.08%
FDMT
4D Molecular Therapeutics
4.61
-13.74
-74.88%

Korro Bio Corporate Events

Executive/Board Changes
Korro Bio CFO Returns from Medical Leave
Neutral
Mar 27, 2025

Korro Bio, Inc. announced that Vineet Agarwal, the Chief Financial Officer, has returned from a temporary medical leave of absence and resumed his duties effective March 27, 2025. The Board of Directors has reappointed him as the principal financial officer. Additionally, Oliver Dolan has been appointed as the principal accounting officer, and he received a stock option award as part of his new role.

Executive/Board ChangesBusiness Operations and Strategy
Korro Bio Appoints Interim CFO Amid Medical Leave
Neutral
Feb 11, 2025

Effective February 11, 2025, Korro Bio, Inc. announced that Vineet Agarwal, the company’s Chief Financial Officer, will be taking a temporary medical leave of absence. In his absence, the Board of Directors has appointed Dr. Ram Aiyar, the President and CEO, as interim principal financial officer, and Mr. Oliver Dolan, Senior Vice President of Finance, as interim principal accounting officer. This reshuffling of responsibilities is a strategic move to ensure continuity in leadership and maintain operational stability during Agarwal’s absence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 24, 2025